Any current/future new fundraising through debt or equity?

Alembic Pharmaceuticals Limited did not mention any current or future new fundraising through debt or equity during the call. The company highlighted that their gross borrowings have reduced from Rs. 686 crores in December 2022 to Rs. 575 crores in December 2023. They reported having Rs. 156 crores of cash on hand as of December 2023. No large CAPEX is planned for the international business other than maintenance CAPEX and some API expansions. The company repaid borrowings and paid dividends from net cash inflows. Overall, the company appears focused on optimizing existing resources and rampin

Any current/future capex/capital investment/strategic investment?

No large CAPEX needed for the international business currently; only maintenance CAPEX and some API expansion planned. API expansion includes growth in therapies such as GLP-1 and debottlenecking. Focus on investments in new capabilities like injectables, peptides, and oncology. The shift toward more complex products aims to reduce price erosion and provide bigger product opportunities, especially in the US market. New facilities are operational but currently have low capacity utilization; operating leverage is expected to improve as product volumes increase. Some targeted CMO (Contr

Future growth expectations in sales/revenue/volumes?

US business: - Expected to grow with broader product portfolio and new product launches (10-15 launches planned in FY25). - Volume increase observed in existing products; new facilities ramp-up to improve operating leverage and margins. - Price erosion continues but is less severe than before; depends on product and competition. - Focus on complex products like injectables, peptides, oncology, which may reduce price erosion and offer larger opportunities. Ex-US markets (Europe, Canada, Australia, Brazil, South Africa): - Steady growth expected at ~15% CAGR, driven through partners.

Future growth expectations in earnings/operating earnings/profits/EPS?

Alembic Pharmaceuticals expects continued growth driven by new product launches, especially in the US generics market with 10-15 launches planned in FY25. The US business is currently profitable and anticipated to improve as operating leverage rises with increased capacity utilization. Operating leverage will improve as new manufacturing facilities ramp up, helping reduce costs and enhance margins. R&D expenses are being optimized, focusing on complex products like injectables, peptides, oncology, and ophthalmics, which should result in better pricing and less erosion. EPS for Q3FY24 before no

Alembic PharmaQ3 FY24Pharmaceuticals & Biotechnology

Alembic Pharma Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹815P/E: 22.8Market Cap: ₹17.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

US business:
- Expected to grow with broader product portfolio and new product launches (10-15 launches planned in FY25).
- Volume increase observed in existing products; new facilities ramp-up to improve operating leverage and margins.
- Price erosion continues but is less severe than before; depends on product and competition.
- Focus on complex products like injectables, peptides, oncology, which may reduce price erosion and offer larger opportunities.
Ex-US markets (Europe, Canada, Australia, Brazil, South Africa):
- Steady growth expected at ~15% CAGR, driven through partners.
API business:
- Continues to be a good margin business with steady growth (~11-15% CAGR).
- Some near-term lumpiness expected, followed by return to regular growth.
Domestic India business:
- 9% growth reported despite muted demand in some segments.
- Specialty therapies and Animal Health showing strong growth.
Overall:
- Incremental operating leverage expected as new facilities grow utilization.
- No major CAPEX planned except maintenance and API expansions.

Margin guidance

Category 3

Alembic Pharmaceuticals expects continued growth driven by new product launches, especially in the US generics market with 10-15 launches planned in FY25.
The US business is currently profitable and anticipated to improve as operating leverage rises with increased capacity utilization.
Operating leverage will improve as new manufacturing facilities ramp up, helping reduce costs and enhance margins.
R&D expenses are being optimized, focusing on complex products like injectables, peptides, oncology, and ophthalmics, which should result in better pricing and less erosion.
EPS for Q3FY24 before non-recurring items is Rs. 9.18 vs. Rs. 6.76 YoY, indicating strong profit growth.
EBITDA margins expected to improve with better capacity utilization and cost control; tax rate normalized at around 17-18% for FY25.
The company anticipates steady revenue growth in ex-US markets (~15% CAGR) and recovery in API business after a temporary slowdown.

See what Alembic Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

Alembic Pharmaceuticals Limited did not mention any current or future new fundraising through debt or equity during the call.
The company highlighted that their gross borrowings have reduced from Rs. 686 crores in December 2022 to Rs. 575 crores in December 2023.
They reported having Rs. 156 crores of cash on hand as of December 2023.
No large CAPEX is planned for the international business other than maintenance CAPEX and some API expansions.
The company repaid borrowings and paid dividends from net cash inflows.
Overall, the company appears focused on optimizing existing resources and ramping up new facilities without raising additional capital through debt or equity at this time.

Order book

The transcript does not explicitly mention current or expected orderbook or pending orders for Alembic Pharmaceuticals Limited. However, relevant points related to business outlook and operations include: - New facilities are operational but currently have low capacity utilization; operating leverage expected to improve as product launches increase. - 11 product launches in Q3 FY24 and about 5 products expected in Q4 FY24, with 10-15 launches anticipated in FY25. - Ongoing evaluations for long-term contracts in the US generics business, but no contracts finalized yet. - Growth in US business volumes and expansion in ex-US markets like Europe, Canada, Australia, Brazil, and South Africa through partners. - Pursuit of CMO (Contract Manufacturing Organization) opportunities to improve plant utilization. - No large CAPEX planned; focus on maintenance and API expansions. No specific quantitative details on orderbook or pending orders are provided in the transcript.

See what Alembic Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes

No large CAPEX needed for the international business currently; only maintenance CAPEX and some API expansion planned.
API expansion includes growth in therapies such as GLP-1 and debottlenecking.
Focus on investments in new capabilities like injectables, peptides, and oncology.
The shift toward more complex products aims to reduce price erosion and provide bigger product opportunities, especially in the US market.
New facilities are operational but currently have low capacity utilization; operating leverage is expected to improve as product volumes increase.
Some targeted CMO (Contract Manufacturing Organization) opportunities are being pursued to improve plant utilization.
No specific timelines or large-scale new capital investments mentioned beyond these incremental expansions and optimizations.

Track Alembic Pharma — get its next earnings analysis in your feed

How does Alembic Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAlembic Pharma

Rev 3Mar 3

See where Alembic Pharma sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Alembic Pharma rank in Pharmaceuticals & Biotechnology?

Compare Alembic Pharma against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Alembic Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Alembic Pharma Q3 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Alembic Pharma rank in Pharmaceuticals & Biotechnology?

Continue your research

What Alembic Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season